跳至主要内容
临床试验/ISRCTN10059974
ISRCTN10059974已完成2 期

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy

Remagus (France)0 个研究点目标入组 340 人开始时间: 2007年2月8日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
340

研究概览

简要总结

  1. 2010 results on pre- and post- therapy detection of circulating tumor cells in http://www.ncbi.nlm.nih.gov/pubmed/19850639 2. 2010 main results in http://www.ncbi.nlm.nih.gov/pubmed/20480225 3. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21525400 4. 2019 results in http://www.ncbi.nlm.nih.gov/pubmed/30702971 [added 01/02/2019]

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Pathologically proven T1c-T4, N0-N1, M0 invasive breast cancer (Tumour, Nodes, Metastasis [TNM] classification)
  • 2. No prior therapy
  • 3. Age 18 to 65 years
  • 4. Available frozen tumour tissue
  • 5. Written informed consent

排除标准

  • 1. Male patient
  • 2. Prior therapy for breast cancer
  • 3. Contraindication to study drug(s)
  • 4. Stage IV breast cancer

研究者

发起方
Remagus (France)

相似试验